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Ramer et al. review the anticancer potential of the canonical
and noncanonical endocannabinoid system. The authors
highlight the regulation of the two canonical receptor subtypes
CB1R and CB2R in malignant tissue, emphasizing the involvement
in cancer onset and progression of the biosynthetic and
degradation enzymes.
Morales and Jagerovic provide a much needed summary of
cannabinoid ligands as promising antitumor agents in a wide
variety of tumors, in contrast to their palliative applications. In
their article, the authors classify cannabinoids with anticancer
potential in endocannabinoids, phytocannabinoids, and synthetic
cannabinoids (arylpyrazoles, aminoalkylindoles, quinones,
naphthyridine, and others) reporting the targeted tumor and the
corresponding mechanism of action of each study these findings.
Moreno et al. in their review explored the value of
cannabinoid receptor heteromers as potential new targets for
anti-cancer therapies and as prognostic biomarkers, showing the
potential of the endocannabinoid network in the anti-cancer
setting as well as the clinical and ethical pitfalls behind it.
As for the antinociceptive potential, Belardo et al. reported a
study performed on cannabidiol (CBD), the major non-
psychoactive constituent of Cannabis sativa, in traumatic brain
injury (TBI). In their research article, the authors evaluated the
CBD effects on the neurological dysfunctions associated with the
TBI demonstrating the ability of oral CBD to prevent allodynia
and neurological dysfunctions in a mouse model of mild TBI.
Jones et al. evaluated the therapeutic effect of indomethacin
morpholinamide (IMMA), a novel substrate-selective COX-2
inhibitor, to alleviate hyperalgesia and mechanical allodynia in
the chronic constriction injury (CCI) mouse model. They
observed that IMMA induced anti-nociceptive effects through
multiple mechanisms including CB2 receptor activation.
As an ensemble, these studies provide further fuel to the
discussion and underline the potential for targeting the ECS at
multiple levels to treat certain cancers and for pain relief.
Importantly, they also help to move the focal point of the
discussion beyond THC, CBD, and the cannonical receptors.
Several of these reports either review or provide data to support
the use of/targeting of other members of the ECS system as well
as alternative natural products beyond THC and CBD. In
summary, we hope that this collection of articles continues to
drive research in what is proving to be a an important area
of research.
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